Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Cash from Operations (2020 - 2026)

Design Therapeutics' Cash from Operations history spans 2 years, with the latest figure at 9227000.0 for Q4 2021.

  • On a quarterly basis, Cash from Operations fell 224.44% to 9227000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was 29377000.0, a 238.87% decrease, with the full-year FY2025 number at 54358000.0, down 26.11% from a year prior.
  • Cash from Operations hit 9227000.0 in Q4 2021 for Design Therapeutics, down from 8164000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for DSGN hit a ceiling of 1307000.0 in Q2 2020 and a floor of 9227000.0 in Q4 2021.